Search

The book discusses the role of gut microbiome composition in colorectal cancer progression, linking intestinal inflammation, tumorigenesis and anti-cancer immune responses. Chapters delve into various areas, including the mechanisms of action of probiotics and prebiotics (such as Lactobacillus and Bifidobacterium strains, and fructans and galactans, respectively), functional foods such as α-carotene, β-carotene, lutein, β-cryptoxanthin, fucoxanthin, isothiocyanates, flavonoids, probiotics, fibre and omega-3. Lycopene, β-cryptoxanthin, and fucoxanthin. Dietary phytochemicals such as polyphenols (curcumin, gingerol, ferulic acid (FA) and hydroxytyrosol); alkaloids (piperine, and protopine); terpenoids (artemisinin, and astaxanthin); iridoid glycoside (picroside II, and morroniside); and flavonoid (quercetin) on cancer, immune responses, and the gut microbiome. It examines the interaction and influence of prebiotics and probiotics in colorectal cancer treatment, their use in managing chemotherapy-related gastrointestinal problems, and their potential as adjuvants. The book also investigates how these gut microbes are associated with tumor progression and anti-cancer treatment efficacy. This knowledge can be used to develop biomarkers that predict immunotherapy effectiveness and improve treatment outcomes through modulation. This book provides a comprehensive update on the latest research and clinical applications in the field, offering valuable insights into the complex interplay between probiotics, the gut microbiome, and colorectal cancer. It serves as an invaluable resource for healthcare professionals, researchers, and students seeking to understand this dynamic area of study.

The worldwide cancer burden will double over the next two decades, with the number of new cancer diagnoses increasing in all regions of the world. However, it is estimated that around 40% of all cancers are preventable through the appropriate application of existing epidemiological and public health knowledge, and with further research this proportion will increase considerably. This edited volume explores the role of place in cancer prevention and how geospatial tools can be used to support this globally important goal. Its chapters detail many aspects of the application of geospatial science to cancer control, including quantifying exposure to environmental carcinogens, access to screening services, the importance of partnership building, and more through a variety of geographically diverse case studies. The book also offers background on geospatial modeling tools and methods for adding spatial analysis to cancer surveillance systems. The book is rooted firmly in the notion that geography significantly influences the accumulation of cancer risks (at the individual and community level) that are modifiable through policy, regulatory, and behavioral changes. The landscape of cancer prevention is vast, encompassing the building blocks of population and public health—i.e., epidemiology and causation—through risk factor modifications, behavior and policy change, to the interface of the cellular with society, including epigenetic modifications and gene/environment interactions, cancer genomics and precision medicine/health. It is clear that geography (space, place, setting, context) is central to all these activities. Geospatial methods and data support risk factor identification, can elucidate the interaction between individual behavioral, demographic, and genetic factors with community level contextual factors, and can be used to prioritize interventions more accurately towards at-risk people and at-risk population groups. Geography is also central to the organization of health services and hence, by definition, is fundamental to the organization of preventative services. More broadly, adopting a geographical approach can help move cancer prevention beyond a narrow medical definition of health, to tackle the upstream and structural determinants of cancer.

The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers. It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments. This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.